Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery

Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery - Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021239

Enrollment

Registered

2016-02-28

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with diabetes mellitus underwent cardiac surgery

Interventions

Canagliflozin 100mg/day for 6months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with DM undergoing Cardiac surgery Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
somatic fat volume (CT)	—

Secondary

Measure	Time frame
HbA1c Body weight, body fat percentage ANP, BNP serum Cr,eGFR HbA1c, glycoalbumin, insulin, CPR U-alb cystatin C, ox-LDL, Lp (a), RLP-cho, EPA/AA renin, angitennsin-II, Aldosterone T-cho,LDL,HDL.TG FMD, ABI, PWV UCG Bood pressure complication	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026